Efficacy Of Crisaborole In The Treatment Of Mild To Moderate Atopic Dermatitis

Objective To evaluate the efficacy and safety of crisaborole in the treatment of mild to moderate atopic dermatitis.Methods A total of one hundred and twenty patients with atopic dermatitis,who met the inclusion criteria of this study were selected,including 60 adults and 60 children.They were randomly divided into two groups.In the experimental group,30 adults and 30 children were both treated with crisaborole;In the control group,30 children were treated with 0.03%tacrolimus,and 30 adults were treated with 0.1% tacrolimus.All the drugs in each group were used externally twice a day.The whole trail lasted for 4 weeks and was divided into three visits.The SCORAD scores,quality of life scores and adverse effects that occurred throughout the trial were recorded for each group before treatment,at the end of treatment 2and 4 weeks.The treatment efficiency,improvement of skin lesion area,clinical signs and symptoms,change in quality of life scores and safety evaluation were compared between the experimental children group and the control children group,the experimental adult group and the control adult group at the end of treatment.Results1.A total of 120 patients with mild to moderate atopic dermatitis were included in this study for clinical observation,including the experimental children group,the control children group,the experimental adult group and the control adult group,each group for 30 patients.There was no significant difference in baseline information such as general clinical data and pre-treatment efficacy indexes between the experimental children group and the control children group,the experimental adult group and the control adult group.(P>0.05).2.Comparison of treatment efficiency: the efficiency rates at the end of 2 and 4 weeks of treatment were 33.33% and 73.33% respectively in the experimental children group,while30.00% and 63.67% respectively in the control children group,the efficiency rate at the end of 4 weeks was higher than 2 weeks in the two groups(P<0.05),but there was no statistical difference between the efficiency rates of the two groups in the same treatment cycle in the intergroup comparison(P>0.05).The efficiency rates at the end of 2 and 4 weeks of treatment were 30.00% and 70.00% respectively in the experimental adult group,while 30.00% and66.67% respectively in the control adult group,the efficiency rate at the end of 4 weeks was higher than 2 weeks in the two groups(P<0.05),but there was no statistical difference between the efficiency rates of the two groups in the same treatment cycle in the intergroup comparison(P>0.05).3.Improvement in lesion area: the lesion area in the experimental children group decreased from 7.53% at baseline to 6.13% at 2 weeks and 4.37% at 4 weeks,while the lesion area in the control children group decreased from 6.70% at baseline to 5.10% at 2 weeks and3.93% at 4 weeks,with no statistical difference between groups(P>0.05);the lesion area in the experimental adult group decreased from 11.57% at baseline to 9.33% at 2 weeks and8.10% at 4 weeks,while the lesion area in the control adult group decreased from 9.13% at baseline to 7.63% at 2 weeks and 6.30% at 4 weeks,with no statistical difference between the groups(P>0.05).4.Improvement of clinical signs: The improvement of erythema,papulation or oedema,excoriations,crusts,lichenification and dryness at the end of 2 and 4 weeks of treatment were compared between the experimental children group and the control children group,between the experimental adult group and the control adult group.Statistical analysis showed that,compared with baseline,all indexes in each group were improved at the end of 4 weeks after the treatment(P<0.05).There was no significant difference in the improvement of the clinical signs between groups compared with the same treatment period(P > 0.05).5.The improvement of clinical symptoms: The improvement of pruritus and sleep disturbance scores at the end of 2 and 4 weeks of treatment were compared between the experimental children group and the control children group,between the experimental adult group and the control adult group.Statistical analysis showed that,compared with baseline,all indexes in each group were improved at the end of 4 weeks after the treatment(P<0.05).There was no significant difference in the improvement of the two symptoms between groups compared with the same treatment period(P > 0.05).6.Comparison of quality of life scores: the quality of life scores of the experimental children group decreased from 6.27 at baseline to 3.50 at 2 weeks and 1.80 at 4 weeks,while the quality of life scores of the control children group decreased from 5.87 at baseline to 3.07 at 2 weeks and 1.40 at 4 weeks,with no statistical difference between groups(P>0.05);the quality of life scores of the experimental adult group decreased from 6.33 at baseline to 4.13 at 2 weeks and 2.00 at 4 weeks,and the quality of life scores of the control adult group decreased from 4.83 at baseline to 3.60 at 2 weeks and 1.80 at 4 weeks,with no statistical difference between the groups(P>0.05).7.Comparison of the incidence of adverse reactions: During the treatment,patients who experienced adverse reactions all manifested as burning,tingling or itching aggravation of the skin at the application site.The incidence of adverse reactions in the experimental children group and the control children group were 6.67% and 46.67%,respectively,it was statistically different between the two groups(P<0.001).the incidence of adverse reactions in the experimental adult group and the control adult group were 10.00% and 56.67%,respectively,it was statistically different between the two groups(P<0.001).Conclusion1.Crisaborole can effectively treat mild to moderate AD patients,with comparable efficacy compared with different concentrations of tacrolimus.2.The adverse effects of crisaborole in the treatment of patients with mild to moderate AD all manifested as burning,tingling or itching aggravation of the skin at the application site,with lower incidence of adverse effects compared with different concentrations of tacrolimus.3.The efficacy of 4 weeks’ using of crisaborole was better than 2 weeks,and the appropriate extension of treatment course would result in more significant improvement in disease severity,clinical signs and symptoms,and quality of life in AD patients.